期刊文献+

慢性丙型肝炎患者血清白介素-8表达水平与基因型及抗病毒治疗的相关性

Relationship of expression level of serum IL-8 with HCV genotypes and antivirus treatment in patients with chronic hepatitis C
原文传递
导出
摘要 目的探讨慢性丙型肝炎患者血清白介素-8(IL-8)水平与丙型肝炎病毒(HCV)感染、基因型及抗病毒治疗的关系。方法对74例慢性丙型肝炎患者应用基因芯片法进行基因型检测,应用双抗体夹心ABC-ELISA法检测患者血清IL-8。比较不同基因型患者之间IL-8水平的差别,观察了抗病毒治疗12周后IL-8水平的变化。结果慢性丙型肝炎患者及健康对照组血清IL-8水平分别为(42.95±50.00)pg/mL及(11.06±1.39)pg/mL(P<0.01);基因1b型慢丙肝患者(46例)及基因2a型患者(28例)IL-8水平分别为(52.72±60.67)pg/mL及(26.93±13.97)pg/mL(P<0.05)。抗病毒治疗后HCV RNA转阴者,其IL-8水平由(41.20±25.89)pg/mL降至(23.89±10.59)pg/mL(P<0.01)。结论慢丙肝患者血清IL-8水平较健康对照组明显升高,且以感染HCV基因1b型者更明显。抗病毒治疗HCV RNA阴转后,其IL-8水平明显回降。 Objective To study the relationship of expression level of serum interleukin-8(IL-8) and HCV genotypes in patients with chronic hepatitis C and observe the change of serum IL-8 level after antivirus treatment.Methods HCV genotypes were determined using DNA chip assay in 74 chronic hepatitis C patients.Serum IL-8 of these patients was determined using bi-antibody sandwich ABC-ELISA assay.Levels of IL-8 in chronic hepatitis C patients with different genotypes were compared.The change of IL-8 level after 12 weeks of antivirus treatment was observed.Results Levels of serum IL-8 in chronic hepatitis C patients and healthy controls were(42.95±50.00)pg/mL and(11.06±1.39)pg/mL,respectively(P0.01),and in patients infected with genotype 1b and genotype 2a were(52.72±60.67)pg/mL and(26.93±13.97)pg/mL,respectively(P0.05).After 12 weeks of antivirus treatment,the serum IL-8 level in patients with undetectable HCV RNA decreased from(41.20±25.89)pg/mL to(23.89±10.59)pg/mL(P0.01).Conclusions The serum level of IL-8 in patients with chronic hepatitis C significantly increases compared with that in healthy controls.The IL-8 level in patients with genotype 1b is higher than that in patients with genotype 2a.The IL-8 level in patients with undetectable HCV RNA significantly decreases after antivirus treatment.
出处 《山东大学学报(医学版)》 CAS 北大核心 2010年第8期100-102,共3页 Journal of Shandong University:Health Sciences
基金 济南市卫生局资助项目(2005-83)
关键词 肝炎 丙型 慢性 白介素-8 基因型 抗病毒治疗 Hepatitis C Chronic Interleukin-8 Genotype Antivirus treatment
  • 相关文献

参考文献9

  • 1Koo B C, McPoland P, Wagoner J P, et al. Relationships between hepatitis C virus replication and CXCL-8 production in vitro [J]. J Virol, 2006, 80 ( 16 ) : 7885- 7893.
  • 2Cacopardo B, Nigro L, Nunnari G, et al. Association between raised IL-8 Serum levels and resistance to combined peg-interferon plus ribavirin therapy in HCV + active chronic hepatitis[J]. Infez Med, 2008, 16(2) :80-85.
  • 3丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 4中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14012
  • 5Mao H J, Lu Z M, Zhang H L, et al. Colorimetric oligonucleotide array for genotyping of hepatitis C virus based on the 5'non-coding region[J]. Clin China Acta, 2008, 388(1-2) :22-27.
  • 6Mahmood S, Sho M, Yasuhara Y, et al. Clinical significance of intrahepatic interleukin-8 in chronic hepatitis C patients[J]. Hepatol Res, 2002, 24(4) :413-419.
  • 7Girard S, Shalhoub P, Lescure P, et al. An altered cellular response to interferon and up-regulation of intedeukin- 8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis[J]. Virology, 2002, 295 ( 2 ) : 272-283.
  • 8王健,赵金红,江水清,项桂菊.丙型肝炎病毒慢性感染与IL-8、IP-10、Mig表达相关性研究[J].第三军医大学学报,2006,28(13):1420-1423. 被引量:11
  • 9El-Shamy A, Nagano-Fujii M, Sasase N, et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy[J].Hepatology, 2008, 48 ( 1 ) : 38- 47.

二级参考文献24

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献14693

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部